Silo Pharma Takes Next Step in Bringing Homing Peptide Tech to $30+ Billion RA Market

Rheumatoid arthritis, or RA, is an autoimmune and inflammatory disease that causes painful swelling in joints in the hands, wrists, and knees. While medications can slow the disease and prevent joint deformity, there is no cure for the condition, and many millions still suffer from it.

Silo Pharma Inc. (OTCQB: SILO) is a development-stage biopharmaceutical company leveraging homing peptides to improve cellular targeting. In RA, the company hopes to deliver dexamethasone via peptide-guided liposomes to enhance its efficacy and toxicity profile.

Let’s take a look at the company’s recent move toward commercialization, as well as how its underlying technology could pave the way for expansion into other markets.

Moving Toward Commercialization

Silo Pharma extended its exclusive option agreement with the University of Maryland-Baltimore earlier this month to explore a novel intervention, generally known as “joint-homing peptides for use in the investigation and treatment of arthritogenic processes,” which has shown a lot of promise in early-stage research in targeting specific cells.

The company subsequently entered into a Scientific Research Agreement with the university to evaluate the pharmacokinetics of dexamethasone delivered to arthritic rats via its peptide-guided liposomes. By selecting an FDA-approved drug, the researchers can focus on delivering the maximum possible dose to specific areas.

Click here to receive investor information and corporate updates

“This agreement is a milestone for the company as we add a significant addressable market for our therapeutic approach,” said Chairman and CEO Eric Weisblum in a press release. “This study will … help establish our hypothesis that we can not only target parts of the body but can lower toxicity and help keep healthy organs unexposed to therapeutics.”

Expansion into Psychedelics

Silo Pharma believes that the same peptide-guided liposomes are adaptable to other drugs because liposomes can be loaded with both hydrophobic and hydrophilic drugs, permitting combination drug therapies. These drugs include emerging psychedelic medicines, such as ketamine and psilocybin for mental health conditions.

In addition to their work with the University of Maryland-Baltimore, the company is working with the University of California-San Francisco via a Scientific Research Agreement to study psilocybin as an anti-inflammatory agent in Parkinson’s disease and bipolar disorder. The study is taking place via the Translational Psychedelic Research Program. 

The company is also waiting on a Netherlands-based investigator-led study of psilocybin to treat Parkinson’s disease, submitted for ethics board review in May, and entered into a joint venture with Zylo Therapeutics to develop a transdermal ketamine therapeutic, among other efforts in the psychedelics space.

Looking Ahead

Silo Pharma Inc. (OTCQB: SILO) has made significant progress in advancing its homing peptide-based technology into rheumatoid arthritis and other markets. Leveraging the same technology platform, the company hopes to target a wide range of different drugs, enabling more efficacy and an improved patient safety profile.

Click here to receive investor information and corporate updates

The company also continues to build and monetize its intellectual property through licensing agreements, such as its agreement with Alkido Pharma Inc. (NASDAQ: AIKI) earlier this year. Under these agreements, the company could receive upfront cash payments and ongoing royalty payments on products developed with the technology.

For more information about Silo Pharma, visit the company’s website or download their investor presentation.

Disclaimer

The above article is sponsored content. CannabisFN.com and CFN Media, have been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: http://www.cannabisfn.com/legal-disclaimer/

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.